Literature DB >> 26715274

Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.

Kheirollah Yari1, Mehrdad Payandeh2, Zohreh Rahimi3,4.   

Abstract

Breast cancer is the most common cancer with high morbidity and mortality among women worldwide. Aberrant hypermethylation in promoter regions of the tumor suppressor genes such as PTEN gene is a key event in the progression and development of breast cancer. The aim of the present study was to evaluate an association between PTEN gene methylation status with the risk of breast cancer in an Iranian population. We studied 255 individuals, including 103 patients with breast cancer, 102 first-degree female relatives of patients (mother, sister, or daughter of patients), and 50 healthy individuals as a control group. Genomic DNA was extracted from peripheral blood leukocytes, and the PTEN promoter methylation status was detected using methylation-specific PCR (MSP) method with specific methylated and unmethylated primers. In some samples, direct DNA sequencing was used to confirm the results obtained by the MSP method. The frequency of PTEN-methylated (MM) genotype was 6 % in the healthy control group, 23.3 % in relatives of patients, and 41.7 % in patients (χ (2) = 24.62, p < 0.001). There were significant differences in the frequency of PTEN-methylated genotype between healthy control compared to that in patients (χ (2) = 15.1, p < 0.001) and also compared to that in relatives of patients (χ (2) = 6.9, p = 0.009). In the presence of PTEN MM genotype, there was a 3.1-fold susceptibility to breast cancer compared to the UU genotype (p < 0.001). Also, in the presence of PTEN M allele, the risk of breast cancer was 2.71-fold compared to the presence of U allele (p < 0.001). Our findings indicated increased frequency of hypermethylation of PTEN promoter in the studied patients and their relatives that could be considered as one of the epigenetic factors affecting the risk of breast cancer in Iranians.

Entities:  

Keywords:  Breast cancer; Epigenetic; Iranian population; Methylation; Methylation-specific PCR; PTEN

Mesh:

Substances:

Year:  2015        PMID: 26715274     DOI: 10.1007/s13277-015-4731-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

1.  PTEN gene is infrequently hypermethylated in human esophageal squamous cell carcinoma.

Authors:  Zhenguo Sun; Na Ji; Mingming Bi; Shuai Wang; Xiangyan Liu; Zhou Wang
Journal:  Tumour Biol       Date:  2015-02-28

2.  The MMP-2 -735 C allele is a risk factor for susceptibility to breast cancer.

Authors:  Kheirollah Yari; Ziba Rahimi; Mohamad Taher Moradi; Zohreh Rahimi
Journal:  Asian Pac J Cancer Prev       Date:  2014

3.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Authors:  M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

4.  Epigenetic marks in estrogen receptor alpha CpG island correlate with some reproductive risk factors in breast cancer.

Authors:  Pantea Izadi; Mehrdad Noruzinia; Forouzandeh Fereidooni; Zahra Mostakhdemine Hosseini; Fatemeh Kamali
Journal:  Mol Biol Rep       Date:  2014-08-19       Impact factor: 2.316

5.  Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer.

Authors:  Zohreh Rahimi; Kheirolah Yari; Ziba Rahimi
Journal:  Asian Pac J Cancer Prev       Date:  2015

6.  Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.

Authors:  Aslaug Aa Muggerud; Jo Anders Rønneberg; Fredrik Wärnberg; Johan Botling; Florence Busato; Jovana Jovanovic; Hiroko Solvang; Ida Bukholm; Anne-Lise Børresen-Dale; Vessela N Kristensen; Therese Sørlie; Jörg Tost
Journal:  Breast Cancer Res       Date:  2010-01-07       Impact factor: 6.466

7.  Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer.

Authors:  Pantea Izadi; Mehrdad Noruzinia; Morteza Karimipoor; Mohammad Hamid Karbassian; Mohammad Taghi Akbari
Journal:  Cell J       Date:  2012-08-31       Impact factor: 2.479

8.  Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry.

Authors:  Liang Yin; Wei-Juan Cai; Chun-Xia Liu; Yun-Zhao Chen; Jian-Ming Hu; Jin-Fang Jiang; Hong-An Li; Xiao-Bin Cui; Xiang-Yun Chang; Wen Jie Zhang; Kan Sun; Feng Li
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.

Authors:  Kathleen Conway; Sharon N Edmiston; Ryan May; Pei Fen Kuan; Haitao Chu; Christopher Bryant; Chiu-Kit Tse; Theresa Swift-Scanlan; Joseph Geradts; Melissa A Troester; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2014-10-07       Impact factor: 6.466

10.  Specific TaqMan allelic discrimination assay for rs1477196 and rs9939609 single nucleotide polymorphisms of FTO gene demonstrated that there is no association between these SNPs and risk of breast cancer in Iranian women.

Authors:  Mahboobeh Mojaver; Fariborz Mokarian; Mohammad Kazemi; Mansoor Salehi
Journal:  Adv Biomed Res       Date:  2015-07-27
View more
  16 in total

Review 1.  DNA methylation-based variation between human populations.

Authors:  Farzeen Kader; Meenu Ghai
Journal:  Mol Genet Genomics       Date:  2016-11-04       Impact factor: 3.291

2.  Study of association between interleukin-8 - 845 T/C and + 781 C/T polymorphisms with periodontitis disease among population from Western Iran.

Authors:  Mehdi Sajadi; Azin Shahmohammadi; Sanaz Mahmazi; Hoda Bashiri; Mehrdad Bavandpour; Kheirollah Yari
Journal:  Mol Biol Rep       Date:  2018-08-04       Impact factor: 2.316

3.  Clinical impact of PTEN methylation status as a prognostic marker for breast cancer.

Authors:  Amal Ramadan; Maha Hashim; Amr Abouzid; Menha Swellam
Journal:  J Genet Eng Biotechnol       Date:  2021-05-10

Review 4.  Blood-based DNA methylation as biomarker for breast cancer: a systematic review.

Authors:  Qiuqiong Tang; Jie Cheng; Xue Cao; Harald Surowy; Barbara Burwinkel
Journal:  Clin Epigenetics       Date:  2016-11-14       Impact factor: 6.551

5.  CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer.

Authors:  Esperanza Martín-Sánchez; Saioa Mendaza; Ane Ulazia-Garmendia; Iñaki Monreal-Santesteban; Idoia Blanco-Luquin; Alicia Córdoba; Francisco Vicente-García; Noemí Pérez-Janices; David Escors; Diego Megías; Paula López-Serra; Manel Esteller; José Juan Illarramendi; David Guerrero-Setas
Journal:  Oncotarget       Date:  2017-02-28

6.  Inferring Novel Tumor Suppressor Genes with a Protein-Protein Interaction Network and Network Diffusion Algorithms.

Authors:  Lei Chen; Yu-Hang Zhang; Zhenghua Zhang; Tao Huang; Yu-Dong Cai
Journal:  Mol Ther Methods Clin Dev       Date:  2018-06-21       Impact factor: 6.698

Review 7.  Genetic and molecular biology of breast cancer among Iranian patients.

Authors:  Meysam Moghbeli
Journal:  J Transl Med       Date:  2019-07-08       Impact factor: 5.531

8.  Promoter Methylation Status of the Retinoic Acid Receptor-Beta 2 Gene in Breast Cancer Patients: A Case Control Study and Systematic Review.

Authors:  Kheirollah Yari; Zohreh Rahimi
Journal:  Breast Care (Basel)       Date:  2019-01-30       Impact factor: 2.860

Review 9.  The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review.

Authors:  Yi-Min Lu; Feng Cheng; Li-Song Teng
Journal:  Sci Rep       Date:  2016-09-13       Impact factor: 4.379

10.  The association of PTEN hypermethylation and breast cancer: a meta-analysis.

Authors:  Shanshan Luo; Jiansi Chen; Xianwei Mo
Journal:  Onco Targets Ther       Date:  2016-09-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.